MTAP deletions in cancer create vulnerability to targeting of the MAT2A/PRMT5/RIOK1 axis

Cited by (499)

Items 301–400 of 499

1. Collateral lethality: A unique type of synthetic lethality in cancers
   Zichen Zhao, Lingling Zhu, Yu Luo, Heng Xu, Yan Zhang · 2024 · Pharmacology & Therapeutics
2. MTA-cooperative PRMT5 inhibitors from cofactor-directed DNA-encoded library screens
   Jan Andersson, Sanne Cowland, Mikkel Vestergaard, Yajing Yang, Siyuan Liu, Fang Xie, Susmith Mukund, Sudipa Ghimire-Rijal, Chris Carter, Grace Chung et al. · 2025 · Proceedings of the National Academy of Sciences
3. Synthesis and Activity of Triazole-Adenosine Analogs as Protein Arginine Methyltransferase 5 Inhibitors
   Tyler M. Brown, Mengtong Cao, Yujun George Zheng · 2022 · Molecules
4. Riok1, A Novel Potential Target in MSI-High p53 Mutant Colorectal Cancer Cells
   Sharon Shechter, Sapir Ya’ar Bar, Hamdan Khattib, Matthew J. Gage, Dorit Avni · 2023 · Molecules
5. MTAP-ANRIL gene fusion promotes melanoma epithelial-mesenchymal transition-like process by activating the JNK and p38 signaling pathways
   Zhuoying Lin, Yu Lei, Mingyao Wen, Qin He, Dean Tian, Huaping Xie · 2023 · Scientific Reports
6. RETRACTED: PRMT5 participates in B cell overactivation in patients with primary Sjogren's syndrome (pSS) through RSAD2‐mediated NF‐κB signaling
   Hong Zhu, Jian Zheng, Yan Zhou, Tong Wu, Tiantian Zhu · 2023 · Immunity Inflammation and Disease · Retracted
7. Cancer biology functional genomics: From small RNAs to big dreams
   Soumya Sundara Rajan, Katelyn R. Ludwig, Katherine L. Hall, Tamara L. Jones, Natasha J. Caplen · 2020 · Molecular Carcinogenesis
8. Genetic Variants and Somatic Alterations Associated with MITF-E318K Germline Mutation in Melanoma Patients
   Elisabetta Vergani, Simona Frigerio, Matteo Dugo, Andrea Devecchi, Erika Feltrin, Loris De Cecco, Viviana Vallacchi, Mara Cossa, Lorenza Di Guardo, Siranoush Manoukian et al. · 2021 · Genes
9. Repression of PRMT activities sensitize human homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment
   Youyou Zhang, Mu Xu, Jiao Yuan, Zhongyi Hu, Junjie Jiang, Yanrong Sun, Jie Sheng Huang, Yuxin Wang, Bingwei Wang, Jianfeng Shen et al. · 2024 · eLife
10. Clinical Presentation of MTAP Deletions in Real-World Settings: Lessons for the Clinical Development of Novel Targeted Therapies
    Jordan T. Best, Xiaotong Fu, Sripraharsha S Jampana Raju, Daniel J. Luckett, Dan Schlauch, Abigail Bradley, Vivek Subbiah, Melissa Lynne Johnson, David Robert Spigel, Howard A. Burris et al. · 2025 · JCO Precision Oncology
11. Unraveling the potential of targeting methionine metabolism in cancer
    Bang-Qi Wang, Xu-Chu Li, Zhenyu Huo, Kai Zeng, Shen Chen, Yuning Wang, Yiming Zhu, Yuyang Huang, Jiatong Ding, Yuanting Cai et al. · 2026 · Cancer Letters
12. Gene fusions during the early evolution of mesothelioma correlate with impaired DNA repair and Hippo pathways
    Maymun Jama, Min Zhang, Charlotte Poile, Apostolos Nakas, Annabel Jane Sharkey, Joanna Działo, Alan G. Dawson, Kudzayi H Kutywayo, Dean Anthony Fennell, Edward J. Hollox · 2023 · Genes Chromosomes and Cancer
13. Concordance between CDKN2A homozygous deletion and MTAP immunohistochemical loss in fluoroedenite-induced pleural mesothelioma: An immunohistochemical and molecular study on a single-institution series
    Giuseppe Broggi, Michele Massimino, Maria Failla, Veronica Filetti, Venerando Rapisarda, Caterina Ledda, Claudia Lombardo, Carla Di Loreto, Paolo Giovanni Vigneri, Rosario Caltabiano · 2024 · Pathology - Research and Practice
14. Epigenetics and alternative splicing in cancer: old enemies, new perspectives
    Madhura R. Pandkar, Sanjeev Shukla · 2024 · Biochemical Journal
15. Prognostic Role of MTAP Loss in Cholangiocarcinoma
    James Lyon, Soravis Alm Osataphan, Vaibhav Birda, Brian M. Russell, Charly Edmiston, Rodrigo Paredes, Ahmed Rattani, Mary Linton B. Peters · 2025 · JCO Precision Oncology
16. A BRET biosensor for measuring uncompetitive engagement of PRMT5 complexes in cells
    Elisabeth M. Rothweiler, Ani Michaud, Jakub Stefaniak, Usha Singh, Brynwood B. Mikulsky, James D. Vasta, Michael Beck, Jennifer Wilkinson, Jennifer Ward, Catherine M. Rogers et al. · 2025 · Nature Communications
17. MTAP-Null Tumors: A Comprehensive Review on Synthetic Vulnerabilities and Therapeutic Strategies
    Bavani Subramaniam, Wai Chin Chong, Aylar Babaei, Miriam Bornhorst, Chunchao Zhang, Roger J. Packer, Javad Nazarian · 2025 · Cells
18. Current and emerging therapies in IDH-mutant glioma
    Vihang Nakhate, Gilbert Youssef, Patrick Yung Wen · 2026 · Neurotherapeutics
19. New insight into targeting the DNA damage response in the treatment of glioblastoma
    Tengfei ZHEN, Tianyu Sun, Baichen XIONG, Hui Liu, Lei Wang, Yao Chen, Haopeng Sun · 2024 · Chinese Journal of Natural Medicines
20. Norcantharidin inhibits the METTL16/MAT2A pathway to induce apoptosis and suppress tumor progression in ovarian cancer
    Yuanyuan Zhang, Qiu-Xia Zeng, Li Wang, Kong-Xian Li, Shun Zhang, Ping Wan, Xueming Zhou, Qi Chen · 2025 · Archives of Biochemistry and Biophysics
21. Capturing Unicorns: Targeting Cancers With TP53 Mutations, RAS Alterations Beyond G12C, and MTAP Loss—No Target Is Out of the Realm of Possibility
    Pooja Anil Shah, Klas G. Wiman, Karen M. Cichowski, Jordi Ahnert Rodon · 2025 · American Society of Clinical Oncology Educational Book
22. A Multi-Scale Computational Approach to Understanding Cancer Metabolism
    Ángelo Lucia, Peter A. DiMaggio · 2019 · Springer eBooks
23. Present and future perspectives for targeting histone modifications in therapy
    Vânia Camilo, Cármen Jerónimo · 2020 · Elsevier eBooks
24. Discovery of Novel PRMT5 Inhibitors Bearing a Methylpiperazinyl Moiety
    Xinyu Bai, Zheng Zhai, Xuyang Zhao, Ridong Li, Ling Liang, Yan Jin, Yuxin Yin · 2022 · Future Medicinal Chemistry
25. Predicting prognosis and immunotherapeutic response of clear cell renal cell carcinoma
    Jun Wang, Weichao Tu, Jianxin Qiu, Dawei Wang · 2022 · Frontiers in Pharmacology
26. Mammalian Chemical Genomics towards Identifying Targets and Elucidating Modes‐of‐Action of Bioactive Compounds
    Ken Matsumoto, Minoru Yoshida · 2021 · ChemBioChem
27. Synthetic lethality in MTAP-deleted tumors: a promising avenue through targeted disruption of the protein methylation pathway
    Luca Boscolo Bielo, Giuseppe Curigliano · 2024 · Annals of Oncology
28. Molecular Insights into Pleural Mesothelioma: Unveiling Pathogenic Mechanisms and Therapeutic Opportunities
    Teodora Zahiu, Carmen Mihaela Mihu, Adina Bianca Boşca, Mariana Viorica Mărginean, Lavinia Patricia Mocan, Roxana-Adelina Lupean, Rada Teodora Suflețel, Carina Mihu, Carmen Stanca Melincovici · 2025 · Diagnostics
29. Methylthioadenosine Phosphorylase (MTAP) and p16 Expression in Melanocytic Nevi and Melanoma with Molecular Correlation
    Liston He, Jason L. Hornick, Eleanor E. Russell-Goldman · 2025 · American Journal of Dermatopathology
30. Impact of molecular tests and precision oncology on patients with advanced thyroid carcinomas in a referral center: the OrienTHYring real-world study
    E. Colombo, Stefano Cavalieri, Andrea Vingiani, Luca Agnelli, Matteo Duca, Biagio Paolini, Franco Perrone, Elena Tamborini, I. Capone, Alessandro Piccolo et al. · 2025 · ESMO Open
31. Emerging roles for methionine metabolism in immune cell fate and function
    Shaojuan Liu, Xiao‐Tian Tang, Min Huang, Jianian Tang, Yiwen Yang · 2025 · Frontiers in Immunology
32. Clinical Importance of Molecular Biomarkers in Pleural Mesothelioma
    Logan Roof, Kenna Koehler, Claire F. Verschraegen · 2026 · Cancers
33. Inhibitory Effect of PRMT5/ MTA Inhibitor on MTAP ‐Deficient Glioma May Be Influenced by Surrounding Normal Cells
    Yunjie Wang, Xiaohui Sun, Runchen Ma, Xiaofan Zhang, Shengmin Ji, Zhaofeng Liu, Gangqiang Yang, Hongbo Wang, Peng Zhang, Jianzhao Zhang et al. · 2024 · Cancer Medicine
34. AMINO ACID COMPOSITION OF PROTEIN OF GLYCINE MAX (L.) MERR. GRAIN VARIETIES OF THE AMUR BREEDING
    Sergey Evgen'evich Nizkiy, Galina Kodirova, Galina Zagumennaya · 2025 · Вестник Красноярского государственного аграрного университета
35. Satraplatin Demonstrates High Cytotoxic Activity Against Genetically Defined Lymphoid Malignancies
    Thilo Zander, Jia Xue, GABRIEL MARKSON, Felix Dahm, CHRISTOPH RENNER · 2022 · Anticancer Research
36. Genetic dependencies associated with transcription factor activities in human cancer cell lines
    Venu Thatikonda, Verena Supper, Johannes Wachter, Onur Kaya, Anju Kombara, Ceren Bilgilier, Madhwesh C. Ravichandran, Jesse Lipp, Rahul Sharma, Lukas Badertscher et al. · 2024 · Cell Reports
37. Mechanistic safety assessment via multi-omic characterisation of systemic pathway perturbations following in vivo MAT2A inhibition
    Valentina Fogal, Filippos Michopoulos, Andrew F. Jarnuczak, Ghaith M. Hamza, Stephanie Harlfinger, Paul R. J. Davey, Heather Hulme, Stephen J. Atkinson, Piotr Gabrowski, Tony Cheung et al. · 2024 · Archives of Toxicology
38. Nutrient control of splice site selection contributes to methionine addiction of cancer
    Dawei Lin, Francisco Carranza, Stacey L. Borrego, Linda Lauinger, Lucas Dantas de Paula, Harika Reddy Pulipelli, Anna Andronicos, Klemens J. Hertel, Peter Kaiser · 2025 · Molecular Metabolism
39. New Drugs for Recurrent or Metastatic Nasopharyngeal Cancer
    Olubukola Ayodele, Lillian L. Siu · 2021 · Springer eBooks
40. Therapeutic Targeting of Methylthioadenosine Phosphorylase
    2016 · Cancer Cell & Microenvironment
41. Remember why we work on cancer
    Levi A. Garraway · 2017 · Nature
42. A role for protein arginine methyltransferase 7 in repetitive and mild traumatic brain injury
    Christina H. Acosta, Garrett A. Clemons, Cristiane Teresinha Citadin, William C. Carr, Mariana Sayuri Berto Udo, Vesna Tešić, Henry W. Sanicola, Anne H. Freelin, Jamie Toms, Joseph Dedrick Jordan et al. · 2023 · Neurochemistry International
43. A Self-Assembling Immune-Featured Osteosarcoma Patient/PDX Derived Organoid Model and Biobank for Personalized Immune Therapy
    Haoran Mu, Yining Tao, Jinzeng Wang, Xin He, Qi Zhang, Weixi Chen, Bing Yao, Sen Ding, Xiyu Yang, Liyuan Zhang et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
44. Chromatin Regulatory Targets for Anticancer Therapeutics
    Paige A. Barta, Trever R. Carter, Michael A. Erb · 2025 · Chemical Reviews
45. Tumor suppressor collateral damage screens reveal mRNA homeostasis protein HBS1L as a novel vulnerability in ch9p21 driven FOCAD deleted cancer
    Hongxiang Zhang, Matthew R. Tonini, Lauren Catherine M. Martires, Helena N. Jenkins, Charlotte B. Pratt, Eden N. Gordon, Shan-Chuan Zhao, Ashley H. Choi, Samuel R. Meier, Tenzing Khendu et al. · 2025 · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
46. Development of a Manufacturing Route toward AMG 193, an MTA-Cooperative PRMT5 Inhibitor
    Athimoolam Arunachalampillai, Prashantha Chandrappa, Richard D. Crockett, Colin S. Gaines, Kelly Hu, Ted C. Judd, Venkata Chandrasekhar Kommuri, James I. Murray, John Nidhiry, Adrian Ortiz et al. · 2025 · Organic Process Research & Development
47. Immune suppression in MTAP-deficient cancers via glutamate metabolism and CXCL10 downregulation
    Wen-Hsin Chang, Jun Zhang, Qi‐Sheng Hong, Ching‐Hsien Chen · 2025 · Frontiers in Immunology
48. Furo[2,3- f ]quinazolin-7(6 H )-one Derivatives as Potent, Selective, and Orally Bioavailable MAT2A Inhibitors for MTAP-Deficient Cancer Therapy
    Zihan Shi, Kexin Lin, Lijie Lin, Zhiyi Chen, Zhiyin Xie, Yaoliang Sun, Rongrong Cui, Sulin Zhang, Mingyue Zheng, Shilin Xu · 2025 · Journal of Medicinal Chemistry
49. Circulating Biomarkers and Targeted Therapy in Pleural Mesothelioma
    Christopher Ryan Grant, Lyudmila A. Bazhenova, Karen M. Yun · 2025 · Cancers
50. Discovery of novel selective PRMT5-MTA inhibitors through structure-based virtual screening
    Ning Ma, Yang Chen, Yiru Liang, Xiaoxu Chen, Fengnan Song, Zhaoming Su, Yajie Wang, Jingyi Zhou, Buying Niu, Yongxin Hao et al. · 2025 · Bioorganic Chemistry
51. Genomic Landscape and Clinical Implications of MTAP Loss in Advanced Gastrointestinal Malignancies
    Lee Min-Ho, Choi Jin-Woo · 2024 · Archive of International Journal of Cancer and Allied Science
52. RETRACTED: Immunometabolism in lung cancer – The link between metabolism and immune response
    Yasamin Eivazzadeh, Niloufar Orooji, Tamana Eskandari, Mahdieh Tarahomi, Fatemeh Tavassoli Razavi, Dariush Haghmorad · 2026 · iScience · Retracted
53. Reconstruction of T cell infiltration in an osteosarcoma PDX-organoid interactive biobank for personalized immunotherapy
    Wei Sun, Yining Tao, Xin He, Qi Zhang, Xiyu Yang, Haoru Dong, Haoyu Wang, Weixi Chen, Bing Yao, Liyuan Zhang et al. · 2026 · Cell Reports Medicine
54. Context-dependent synthetic lethality — an emerging precision therapeutic approach
    Liang Chang, Katharin L. Shaw, Francisca Vázquez, William R. Sellers · 2026 · Nature reviews. Cancer
55. Targeting key epigenetic regulators in solid tumors: focus on EZH2, PRMT5, and BET inhibitors
    Irene Hernández de Córdoba Sánchez, Mercedes Avedillo Ruidiaz, Victor Moreno, H. W. Long, Paloma Cejas · 2026 · Cancer Treatment Reviews
56. The Discovery of TNG456: A Highly Potent, Selective, Brain-Penetrant MTA-Cooperative PRMT5 Inhibitor for the Treatment of MTAP -Deleted Cancers
    Kevin M. Cottrell, Kimberly J. Briggs, Alice Tsai, Colin Liang, Patrick R. McCarren, Douglas A. Whittington, Minjie Zhang, Wenhai Zhang, Alan Huang, Jannik N. Andersen et al. · 2026 · Journal of Medicinal Chemistry
57. Comprehensive Genomic and Transcriptomic Characterization of MTAP Loss across Advanced Solid Tumors
    Kyosuke Seguchi, Takao Fujisawa, Sadakatsu Ikeda, Yu Oyama, Norio Nonomura, Chigusa Morizane, Hiroji Iwata, Susumu Okano, Hidemichi Watari, Kenjiro Namikawa et al. · 2026 · Clinical Cancer Research
58. Use of Human Dose Prediction Metrics to Enable Discovery of AZD3470, an MTA-Cooperative PRMT5 Inhibitor in Clinical Evaluation
    James M. Smith, Bernard C. Barlaam, David Beattie, Lauren Bradshaw, Ho Man Chan, Sophie L. Cooke, Anna S. Cronin, Iain Cumming, Emma Jane Dean, J.E. Debreczeni et al. · 2026 · Journal of Medicinal Chemistry
59. Novel Synthetic Lethal Therapeutic Strategies in Precision Oncology
    Timothy Anthony Yap, Fiona A. Simpkins, Marie Porte, Sophie C. Postel-Vinay · 2026 · American Society of Clinical Oncology Educational Book
60. Interactions between lncRNAs and cyclins/CDKs complexes; key players in determining cancer cell response to CDKs inhibitors
    Bahaa Ibrahim Saeed, Abhinav Kumar, Enwa Felix Oghenemaro, Layla A. Almutairi, Rekha M. M, Rohit Kumawat, Subasini Uthirapathy, Hanen Mahmod Hulail, Shilpa Sharma, Mohit Kumar · 2025 · Experimental Cell Research
61. Emerging Therapeutic Targets in Pancreatic Adenocarcinoma
    Jennifer Hsing Choe, James L. Abbruzzese · 2016 · Springer eBooks
62. Emerging Therapeutic Targets in Pancreatic Adenocarcinoma
    Jennifer Hsing Choe, James L. Abbruzzese · 2018 · Springer eBooks
63. Targeted Therapies for Pancreatic Cancer
    Michael S. Lee, Shubham Pant · 2023 · Springer eBooks
64. Inhibiting Arginine Methylation
    Gianluca Sbardella, Mark T. Bedford · 2024 · Royal Society of Chemistry eBooks
65. Discovery of MTA-cooperative PRMT5 Inhibitors
    John P. Maxwell, Kevin M. Cottrell, K. Briggs · 2024 · Royal Society of Chemistry eBooks
66. Development of a Commercial Ready Process for TNG908: A Potent, Selective, and Brain-Penetrant MTA-Cooperative PRMT5 Inhibitor
    Jianglin Liang, Hongming Li, Kevin M. Cottrell, Yong Liu, John P. Maxwell, Zhengyang Xin, Luigi Anzalone, Magnus Ronn, Michael A. Palmieri · 2025 · Organic Process Research & Development
67. Discovery of Potential Scaffolds for Methionine Adenosyltransferase 2A (MAT2A) Inhibitors: Virtual Screening, Synthesis, and Biological Evaluation
    Chunchun Qi, Xinghui Yu, Siyu Zuo, Pinsheng Han, Ruilin An, Yamin Zhang · 2025 · Molecules
68. Targeting Metabolic Reprogramming: A New Frontier in Cancer Therapy
    Ravi Kumar Thakur, Niti Kumari · 2025 · Springer eBooks
69. Exploiting Synthetic Lethality of PRMT5 for Precision Treatment of MTAP-Deficient Glioblastoma
    Trang Thi Thu Nguyen, Eunhee S. Yi, Christian E. Badr · 2025 · International Journal of Translational Medicine
70. Impact of Chromosomal Instability and Aneuploidy in Cancer Development
    Amanda K. Mennie, Brittiny Dhital, Peter Ly · 2025 · Annual Review of Cancer Biology
71. Interferon‐Driven Biomarkers and Synergistic Therapy for PRMT5 Inhibition in Triple‐Negative Breast Cancer
    Ziwen Zhang, She-Yu Zhang, Lu Guo, Yichun Pan, Juan Huang, Yishuai Ji, Jiaqi Tao, Yong Wei, X. Wang, Qin Wu · 2025 · Advancement of science
72. Targeting methionine-induced pyroptosis enhances anti-tumor immunity
    Mingzhu Lei, Wenying Zhu, Chao Wang, Fan Zhang, Miaolin Li, Yi Zhang, Jia Qu, Zhiguo Luo, Jintao Li, Zeng-Xia Li et al. · 2026 · Science China Life Sciences
73. A synergistic interaction between PRMT5 and LSD1 inhibitors in AML
    Nesteene Joy Param, Elisa Arceci, Francesco Fiorentino, Luca Pignata, Denis Torre, Nayeli Gutiérrez, Jia Yi Fong, Pierre-Alexis Vincent Goy, Yuyuan Han, Chiara Lambona et al. · 2026 · Science Advances
74. Clinicogenomic Landscape of MTAP -Deleted Thoracic Malignancies Across US and Japanese Nationwide Cohorts: Impact of Concurrent CDKN2A Alterations and Driver Mutations
    Hiroaki Ikushima, Kousuke Watanabe, Aya Shinozaki-Ushiku, Katsutoshi Oda, Hidenori Kage · 2026 · JCO Precision Oncology
75. Temporal control of sgRNA library activation unlocks large-scale in vivo CRISPR screens
    Silvia Fenoglio, Yi Yu, James Tepper, Lauren Grove, Alborz Bejnood, Samuel R. Meier, Ashley H Choi, Hsin‐Jung Wu, Annabel Devault, Shangtao Liu et al. · 2026 · Cell Reports Methods
76. LKB1 inactivation elicits an NNMT-mediated methyl sink and confers dependence on PRMT5 in lung cancer
    Wen Mi, Xinyi Xia, Yun Xue, Liucheng Li, Li Yang, Xincheng Yang, Jie Xu, Xinlei Cai, Yijia Zhou, Lingzhi Zhu et al. · 2026 · Cell Reports
77. Clinical characteristics and therapeutic implications of MTAP deletion in pancreatic cancer: A nationwide genomic analysis
    Hiroya Matsumoto, Kazuyuki Mizuno, Chiaki Kondo, Hiroki Kawashima, Hideharu Hibi, Yuichi Ando · 2026 · Pancreatology
78. MTAP loss in non–small-cell lung Cancer and beyond: Therapeutic targeting of the MAT2A–PRMT5 axis
    Zhaohui Arter, Joo Sung Gabriel Shim, Cathleen Park, Sarah Waliany, Sun Min Lim, Ross A. Soo · 2026 · Cancer Treatment Reviews
79. Phosphoinositide and redox dysregulation by the anticancer methylthioadenosine phosphorylase transition state inhibitor
    Timothy Salita, Yepy H. Rustam, Vinzenz Hofferek, Michael Jackson, Isaac Tollestrup, Jeffrey P. Sheridan, Vern L. Schramm, Gary B. Evans, Gavin E. Reid, Andrew B. Munkacsi · 2023 · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
80. Network targeting combination therapy of synthetic lethal vulnerabilities in 9p21-deficient glioblastoma: A case report
    Michael P Castro, Kristin M. Dittmar · 2023 · Neuro-Oncology Advances
81. The role of lipoylation in mitochondrial adaptation to methionine restriction
    Jingyuan Xue, Cunqi Ye · 2024 · BioEssays
82. Recent Developments in the Structural Mechanism of Protein Methyltransferase Inhibition
    Rachel Leung, Matthieu Schapira · 2024 · Royal Society of Chemistry eBooks
83. Actitud de los odontológos generales de Murcia en relación con la biopsia oral
    Pía López‐Jornet, Antonio Pablo Velandrino Nicolás, Yolanda Martínez Beneyto, Mercedes Fernández Soria · 2007 · Medicina oral, patología oral y cirugía bucal
84. PRMT Inhibitors
    Matthijs J. van Haren, Nathaniel I. Martin · 2019 · Topics in medicinal chemistry
85. Environmental factors shape methionine metabolism in p16/MTAP deleted cells
    Sydney M. Sanderson, Peter G. Mikhael, Ziwei Dai, Jason W. Locasale · 2018 · bioRxiv (Cold Spring Harbor Laboratory)
86. A Germinal Center-Associated Microenvironmental Signature Reflects Malignant Phenotype and Outcome of Diffuse Large B-cell Lymphoma
    Kohta Miyawaki, Koji Kato, Takeshi Sugio, Kensuke Sasaki, Hiroaki Miyoshi, Yuichiro Semba, Yoshikane Kikushige, Yasuo Mori, Yuya Kunisaki, Hiromi Iwasaki et al. · 2019 · bioRxiv (Cold Spring Harbor Laboratory)
87. A chemical biology toolbox to investigate in-cell target engagement and specificity of PRMT5-inhibitors
    Elisabeth M. Rothweiler, Jakub Stefaniak, Jennifer Ward, Catherine M. Rogers, Esra Balıkçı, K. Huber · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
88. Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment
    Youyou Zhang, Mu Xu, Jiao Yuan, Zhongyi Hu, Junjie Jiang, Jie Sheng Huang, Bingwei Wang, Jianfeng Shen, Meixiao Long, Yi Fan et al. · 2024 · eLife
89. O-mannosylation and protein maturation check-points represent therapeutic opportunities in BRAF fusion protein oncogenesis
    Sean A. Misek, Anna Borgenvik, Daniel Christen, Gloria Kyrila, Alexander Zhang, Sarah Martin Reel, Michelle Boisvert, Ke Xia Cai, Kevin Ning Zhou, Elizabeth Gonzáles et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
90. Targeting the epigenome and immune evasion: a new chapter in PRMT5 inhibition
    Pooja Anil Shah, Jordi Ahnert Rodon · 2025 · Annals of Oncology
91. The Polymerase Associated Factor Complex-Protein Arginine Methyltransferase Axis: A Mechanism of Acute Leukemia
    Justin Serio · 2017 · Deep Blue (University of Michigan)
92. Unmet Needs and Future Outlook of Mesothelioma Management
    Dean Anthony Fennell · 2019 · Springer eBooks
93. Multiomics Characterization of Potential Therapeutic Vulnerabilities in Low-grade Serous Ovarian Carcinoma
    Raunak Shrestha, Marta Llauradó, Amy Dawson, Joshua Hoenisch, Stanislav V. Volik, Yen‐Yi Lin, Shawn A. Anderson, Hannah H. Kim, Anne M. Haegert, Shane Colborne et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
94. The U6 snRNA m6A Methyltransferase METTL16 Regulates MAT2A Intron Retention Through Co-Transcriptional Splicing
    Kathryn E. Pendleton · 2017
95. Promising Investigational New Drugs for Mesothelioma: What Is the Next Stage of the Treatment for Advanced Mesothelioma?
    Dean Anthony Fennell · 2021 · Respiratory disease series
96. Faculty Opinions recommendation of PRMT5 Regulates DNA Repair by Controlling the Alternative Splicing of Histone-Modifying Enzymes.
    Scott A. Ness · 2018 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
97. Discovery of Achiral, Non-Atropisomeric 4-(Aminomethyl)Phthalazin-1(2H)-One Derivatives as Novel PRMT5/MTA Inhibitors
    Christopher R. Smith, Ruth Aranda, James G. Christensen, Lars D. Engstrom, Robin J. Gunn, Anthony Ivetac, John M. Ketcham, Jon E. Kuehler, J. David Lawson, Matthew A. Marx et al. · 2022 · SSRN Electronic Journal
98. Data from MTAP Deficiency–Induced Metabolic Reprogramming Creates a Vulnerability to Cotargeting De Novo Purine Synthesis and Glycolysis in Pancreatic Cancer
    Qiangsheng Hu, Yi Qin, Shunrong Ji, Xiuhui Shi, Weixing Dai, Guixiong Fan, Shuo Li, Wenyan Xu, Wensheng Liu, Mengqi Liu et al. · 2023
99. Data from Selective PRMT5 Inhibitors Suppress Human CD8+ T Cells by Upregulation of p53 and Impairment of the AKT Pathway Similar to the Tumor Metabolite MTA
    Carolin Dorothea Strobl, Stefanie Schaffer, Tabea Haug, Simon Völkl, Katrin Peter, Katrin Singer, Martin Böttcher, Dimitrios Mougiakakos, Andréas Mackensen, Michael Aigner · 2023
100. Characterising Changes in Lipid Homeostasis as an Anti-Cancer Mechanism of Action of Methylthio-DADMe-Immucillin-A
     Timothy Salita · 2018